Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Published:2017-06 Issue:6 Volume:18 Page:732-742
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Diéras Véronique,Miles David,Verma Sunil,Pegram Mark,Welslau Manfred,Baselga José,Krop Ian E,Blackwell Kim,Hoersch Silke,Xu Jin,Green Marjorie,Gianni Luca

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

3. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol,2010

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

5. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group;Marty;J Clin Oncol,2005

Cited by 490 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery;Radiotherapy and Oncology;2024-10

2. Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial;2024-08-27

3. Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial;2024-08-27

4. Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial;2024-08-20

5. Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis;Discover Oncology;2024-08-02